FindTrial
Sign In

The role of blood markers in patients with endometrial cancer to assess the prognosis of disease.

Serum Visfatin and Serum Adiponectin Levels in Patients with Carcinoma Endometrium

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/11/028943
Enrollment
100
Registered
2020-11-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C541- Malignant neoplasm of endometrium

Interventions

Intervention1: Diagnosed cases of endometrial carcinoma: All diagnosed cases of Endometrial Carcinoma Ability to comply with the protocol. Adequate cardiorespiratory, renal and liver functions and w

Sponsors

All India Institute of Medical Sciences New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Cases All diagnosed cases of Endometrial Carcinoma Ability to comply with the protocol. Adequate cardiorespiratory, renal and liver functions and who are fit to undergo surgery. Controls Patients admitted for surgery for benign gynecological conditions (leiomyoma, uterovaginal prolapse, adenomyosis). Endometrial histopathology of uterus and cervix proven negative for malignancy. Ability to comply with the protocol. Adequate cardiorespiratory, renal and liver functions and who are fit to undergo surgery.

Exclusion criteria

Exclusion criteria: Cases • Patients who have already undergone surgical procedures for Endometrial carcinoma • Patients known to have other malignancies • History of hysterectomy, bilateral oophorectomy, or Lynch syndrome • History of use of exogenous hormones Controls • Patients unwilling to participate in the study • Patients known to have other malignancies • History of hysterectomy, bilateral oophorectomy, or Lynch syndrome

Design outcomes

Primary

MeasureTime frame
1.Serum levels of visfatin and adiponectin in patients with carcinoma endometrium and controls 2.Serum levels of visfatin and adiponectin in patients with endometrial carcinoma who had deep myometrial invasion, grade 2/3 disease and lymph node involvement. 3.Serum levels of visfatin and adiponectin in patients with endometrial carcinoma who had no or superficial myometrial invasion, grade 1 disease and without lymph node involvement. Timepoint: After 1 year—

Secondary

MeasureTime frame
1.Visfatin adiponectin ratio (V:A ratio) in patients with carcinoma endometrium 2.Visfatin adiponectin ratio (V:A ratio) in controls Timepoint: After 1 year—

Countries

India

Contacts

Public ContactJyoti Meena

All India Institute of Medical Sciences New Delhi

drjyotirajesh@gmail.com9953937130

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026